| Nom |
Tofacitinib |
| Nom anglais |
Tofacitinib; 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile; 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; 3-{(3S,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile; CP 690550; CP-690550; 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
| Formule moléculaire |
C16H20N6O |
| Poids Moléculaire |
312.3696 |
| InChI |
InChI=1/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13-/m1/s1 |
| Numéro de registre CAS |
477600-75-2 |
| Structure moléculaire |
|
| Densité |
1.296g/cm3 |
| Point d'ébullition |
585.845°C at 760 mmHg |
| Indice de réfraction |
1.646 |
| Point d'éclair |
308.108°C |
| Pression de vapeur |
0mmHg at 25°C |
| Les symboles de danger |
|
| Codes des risques |
|
| Description de sécurité |
|
|
